■由于缺乏可靠的疾病特异性生物标志物,肠易激综合征(IBS)的诊断基于基于症状的标准。肠道菌群在IBS中受到干扰,当比较用于分析肠道菌群的不同方法时,结果可能会模糊。因此,在本系统综述中,我们旨在通过相同方法(基于16SrRNA测序的GA-mapDybiosisTest),调查IBS和IBS亚组患者与健康对照(HC)的粪便细菌标志物和菌群失调指数(DI)的概况.
■我们搜索了PubMed,EMBASE(Ovid)和Cochrane图书馆进行病例对照研究,比较用GA-map®DysbiosisTest分析的粪便肠道微生物群(奥斯陆,挪威)在IBS和HC患者中。我们的结果是与HC相比,IBS和IBS亚组患者的粪便细菌标志物和DI的差异。
■搜索确定了28条引文;包括五篇文章。大多数研究评估了腹泻为主的IBS(IBS-D)患者的粪便细菌标志物和DI。与HC相比,IBS和IBS亚组的粪便细菌谱结果不一致,然而,两项研究显示,与HC相比,IBS-D中的gnavusRuminococus水平升高,DI的结果表明,与HC相比,IBS和IBS亚组(尤其是IBS-D)具有更高的DI。
■本系统综述显示,在使用基于16SrRNA测序的GA-mapDysbiosisTest的研究中,IBS和IBS亚组与HC之间的细菌标记差异的发现不一致。然而,测试很新颖,到目前为止,很少有研究使用这种方法。需要进行更多的研究来比较IBS和IBS亚组与HC相比的粪便微生物群分布差异,以利用相同的分析方法使我们进一步了解IBS中的肠道细菌分布和肠道菌群失调的临床后果。
UNASSIGNED: The diagnosis of irritable bowel syndrome (IBS) is based on symptom-based criteria due to lack of reliable disease-specific biomarkers. Gut microbiota is perturbed in IBS and when comparing different methods used to analyze gut microbiota, the results might be obscured. Therefore, in this systematic
review we aimed to investigate the profile of fecal bacterial markers and dysbiosis index (DI) in patients with IBS and IBS subgroups compared to healthy controls (HCs) conducted by the same method (GA-map Dysbiosis Test based on16S rRNA sequencing).
UNASSIGNED: We searched PubMed, EMBASE (Ovid) and Cochrane Library for case-control studies comparing fecal gut microbiota analyzed with the GA-map® Dysbiosis Test (Oslo, Norway) in patients with IBS and HCs. Our outcomes were the difference in fecal bacterial markers and DI in patients with IBS and IBS subgroups compared to HCs.
UNASSIGNED: The search identified 28 citations; five articles were included. Most studies evaluated fecal bacterial markers and DI in patients with diarrhea-predominant IBS (IBS-D). Results of fecal bacteria profile in IBS and IBS subgroups compared to HCs are inconsistent, however, two studies showed increased levels of Ruminococcus gnavus in IBS-D compared to HCs and results of DI indicated IBS and IBS subgroups (especially IBS-D) having higher DI compared to HCs.
UNASSIGNED: This systematic
review revealed inconsistent findings in respect to differences in bacterial markers between IBS and IBS subgroups with HCs in studies using the GA-map Dysbiosis Test based on 16S rRNA sequencing. However, the test is quite novel, and few studies have used the method so far. More research comparing fecal microbiota profile differences in IBS and IBS subgroups compared to HCs utilizing the same method of analysis is needed to give us further insight into the gut bacteria profile in IBS and the clinical consequences of intestinal dysbiosis.